Why did reported earnings fall so sharply despite strong sales growth?

Reported Q4 operating income fell 53.8% to $581 million because of $956 million in goodwill and other impairments, mainly tied to the Spine business. This included a $273 million annual goodwill impairment, a $183 million goodwill impairment after the business was classified as held for sale, and a $362 million asset write-down. These are non-cash charges, and management adjusts them out of its non-GAAP earnings figures.

What does the 2025 guidance imply for growth?

Management expects organic net sales growth of 8.0% to 9.0% and adjusted diluted EPS of $13.45 to $13.70, implying roughly 8%-10% adjusted EPS growth versus the 2024 adjusted figure of $12.19. Guidance assumes FX reduces net sales by about 1% and EPS by $0.10 to $0.15, and the Spinal Implants sale is absorbed within the organic growth outlook.

How will the Inari acquisition affect Stryker's results?

Inari is expected to contribute about $590 million of sales in the 2025 stub period from closing in late February. It is projected to dilute adjusted operating margin by 0 to 20 basis points and adjusted EPS by $0.20 to $0.30. The guidance is not stated to include Inari beyond these estimates, so investors should watch for updated figures after the deal closes.

Is Stryker's balance sheet becoming more leveraged?

Yes. Long-term debt, excluding current maturities, rose to $12.2 billion at year-end 2024 from $10.9 billion, and net borrowings in 2024 were $940 million. Acquisition spending of $1.6 billion, largely funding the year's deals, drove this increase. Cash and equivalents also grew to $3.7 billion, and operating cash flow of $4.2 billion comfortably covered $1.2 billion in dividends.

What is the status of the Spine business?

Stryker is divesting its Spinal Implants business, which had been classified as held for sale from November 1, 2024. Sales in that portfolio were flat to down, with full-year 2024 Spinal Implants revenue of $707 million, down 0.7%. The divestiture and related impairments are the main reason for the reported earnings decline, and management says the sale's impact is reflected in the 2025 organic growth guidance.

SYK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 28, 2025. Cited figures are marked; the original filing is the authoritative source.

Stryker's fourth-quarter and full-year 2024 results show strong top-line momentum with underlying profitability improving, but GAAP earnings were hit hard by impairments tied to the Spine business.

Q4 reported net sales rose 10.7% to $6.4 billion^a (10.2% organic), and full-year net sales reached $22.6 billion, up 10.2% (10.2% organic). Adjusted operating margin expanded 200 bps in Q4 to 29.2% and 110 bps for the year to 25.3%, with adjusted EPS up 15.9% to $4.01 in Q4 and 15.0% to $12.19 for the year. Reported results were materially depressed by $818 million of non-cash charges related to Spine, including a $273 million goodwill impairment from the annual test and a further $183 million goodwill impairment plus a $362 million asset impairment after the Spinal Implants business was classified as held for sale.

Q4 reported diluted EPS fell 52.7% to $1.41^b, and full-year reported EPS declined 5.9% to $7.76. Investors should focus on the adjusted metrics with the understanding that the Spine divestiture and impairments represent a real write-down of that franchise. For 2025, management guided to organic net sales growth of 8.0% to 9.0% and adjusted diluted EPS of $13.45 to $13.70, with FX expected to reduce net sales by about 1% and EPS by $0.10 to $0.15.

The guidance excludes the pending Inari Medical acquisition, expected to close around late February, which is projected to add roughly $590 million^c of stub-period sales and dilute adjusted operating margin by 0 to 20 bps and adjusted EPS by $0.20 to $0.30. Balance sheet leverage increased, with long-term debt rising to $12.2 billion from $10.9 billion, reflecting acquisition funding.

02—Key points

Key Highlights

Q4 2024 reported net sales of $6.4 billion, up 10.7% (10.2% organic), with growth across both MedSurg and Neurotechnology (+10.6%) and Orthopaedics (+10.8%)
Full-year 2024 net sales reached $22.6 billion, up 10.2%, with organic growth of 10.2% driven by 9.1% unit volume and 1.1% price
Adjusted operating margin expanded 200 bps in Q4 to 29.2% and 110 bps for the year to 25.3%
Reported Q4 EPS fell 52.7% to $1.41 due to $818 million of non-cash Spine-related goodwill and asset impairments; adjusted Q4 EPS rose 15.9% to $4.01
2025 guidance calls for 8.0%-9.0% organic sales growth and adjusted EPS of $13.45-$13.70, with FX a ~1% sales headwind
Pending Inari Medical acquisition expected to close late February 2025, adding ~$590M of stub-period sales and modest margin and EPS dilution
Spinal Implants business being sold; long-term debt rose to $12.2 billion from $10.9 billion, and operating cash flow grew to $4.2 billion in 2024

03—Questions

Frequently Asked Questions

Why did reported earnings fall so sharply despite strong sales growth?
Reported Q4 operating income fell 53.8% to $581 million because of $956 million in goodwill and other impairments, mainly tied to the Spine business. This included a $273 million annual goodwill impairment, a $183 million goodwill impairment after the business was classified as held for sale, and a $362 million asset write-down. These are non-cash charges, and management adjusts them out of its non-GAAP earnings figures.
What does the 2025 guidance imply for growth?
Management expects organic net sales growth of 8.0% to 9.0% and adjusted diluted EPS of $13.45 to $13.70, implying roughly 8%-10% adjusted EPS growth versus the 2024 adjusted figure of $12.19. Guidance assumes FX reduces net sales by about 1% and EPS by $0.10 to $0.15, and the Spinal Implants sale is absorbed within the organic growth outlook.
How will the Inari acquisition affect Stryker's results?
Inari is expected to contribute about $590 million of sales in the 2025 stub period from closing in late February. It is projected to dilute adjusted operating margin by 0 to 20 basis points and adjusted EPS by $0.20 to $0.30. The guidance is not stated to include Inari beyond these estimates, so investors should watch for updated figures after the deal closes.
Is Stryker's balance sheet becoming more leveraged?
Yes. Long-term debt, excluding current maturities, rose to $12.2 billion at year-end 2024 from $10.9 billion, and net borrowings in 2024 were $940 million. Acquisition spending of $1.6 billion, largely funding the year's deals, drove this increase. Cash and equivalents also grew to $3.7 billion, and operating cash flow of $4.2 billion comfortably covered $1.2 billion in dividends.
What is the status of the Spine business?
Stryker is divesting its Spinal Implants business, which had been classified as held for sale from November 1, 2024. Sales in that portfolio were flat to down, with full-year 2024 Spinal Implants revenue of $707 million, down 0.7%. The divestiture and related impairments are the main reason for the reported earnings decline, and management says the sale's impact is reflected in the 2025 organic growth guidance.

04—Continue

← View all 8-K filings